FDA fast tracks drugs for Ebola and Marburg viruses

News
Article

FDA has granted fast-track designation for the development of AVI-7288 and AVI-7537 (Sarepta Therapeutics), for the treatment of Marburg virus and Ebola virus, respectively.

FDA has granted fast-track designation for the development of AVI-7288 and AVI-7537 (Marburg hemorrhagic fever is a severe and potentially fatal disease in humans first recognized in 1967. It is caused by an RNA virus of the Filoviridae family and is understood to be endemic to Africa. The Marburg virus is classified as a Category A bioterrorism agent by the CDC, and was determined to pose a material threat to national security and public health by the Secretary of Homeland Security in 2006. Onset of the disease is often sudden, and the symptoms include fever, chills, nausea, vomiting, chest pain, and diarrhea. Increasingly severe symptoms may also include massive hemorrhaging and multiple organ dysfunctions. There are currently no treatments for Marburg virus infection beyond supportive care.The hemorrhagic fever caused by the Ebola virus is severe and often fatal in humans. The disease was first recognized in 1976 and is one of 2 members of a family of RNA viruses called Filoviridae. The disease is generally understood to be endemic to parts of Africa. Onset of illness from Ebola virus is abrupt with symptoms that include fever, headache, muscle ache, vomiting, and stomach pain. Internal and external bleeding may also be observed in some patients. There are currently no treatments for Ebola virus infection beyond supportive care and the mortality rate is very high.

Recent Videos
Related Content
UnitedHealth Group CEO Andrew Witty Defends PBMs

UnitedHealth Group CEO Andrew Witty Defends PBMs

Denise Myshko
January 16th 2025
Article

In an investor call, Andrew Witty promised full transparency and 100% pass-through rebates for prescription drugs by 2028.

Read More

© LIGHTFIELD STUDIOS - stock.adobe.com

FDA Accepts BLA for Leqembi Autoinjector

Logan Lutton
January 14th 2025
Article

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The FDA has set a goal date of Aug. 31, 2025.

Read More

Tada Images-stock.adobe.com

New FTC Report: PBMs Mark Up Specialty Generic Drugs

Denise Myshko
January 14th 2025
Article

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and steer patients to their own pharmacies.

Read More

FDA to Hold Ad Comm Meeting for Rexulti in PTSD

FDA to Hold Ad Comm Meeting for Rexulti in PTSD

Formulary Watch
January 10th 2025
Article

The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, originally planned for Feb. 8, 2025, will be delayed.

Read More

Bayer Submits Supplemental NDA for Kerendia in Heart Failure

Bayer Submits Supplemental NDA for Kerendia in Heart Failure

Formulary Watch
January 10th 2025
Article

Kerenida is currently approved to slow the progression of chronic kidney disease associated with type 2 diabetes.

Read More

kitsawet-stock.adobe.com

FDA Requires Guillain-Barré Warning for Abrysvo and Arexvy

Formulary Watch
January 9th 2025
Article

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus continue to outweigh their risks.

Read More

© 2025 MJH Life Sciences

All rights reserved.